Index RUT
P/E -
EPS (ttm) -1.50
Insider Own 18.97%
Shs Outstand 304.62M
Perf Week -9.89%
Market Cap 2.58B
Forward P/E -
EPS next Y -0.83
Insider Trans -0.09%
Shs Float 246.97M
Perf Month -27.36%
Income -410.00M
PEG -
EPS next Q -0.26
Inst Own 68.47%
Short Float 21.86%
Perf Quarter -15.38%
Sales 90.86M
P/S 28.41
EPS this Y 33.29%
Inst Trans 1.73%
Short Ratio 8.61
Perf Half Y 4.05%
Book/sh 2.54
P/B 3.34
EPS next Y 34.44%
ROA -44.48%
Short Interest 53.99M
Perf Year 35.09%
Cash/sh 1.30
P/C 6.49
EPS next 5Y -
ROE -56.65%
52W Range 6.00 - 18.33
Perf YTD 4.18%
Dividend Est. -
P/FCF -
EPS past 5Y -8.25%
ROI -48.76%
52W High -53.79%
Beta 0.53
Dividend TTM -
Quick Ratio 3.90
Sales past 5Y 0.00%
Gross Margin -19.74%
52W Low 41.17%
ATR (14) 0.57
Dividend Ex-Date -
Current Ratio 4.22
EPS Y/Y TTM 28.07%
Oper. Margin -473.22%
RSI (14) 39.48
Volatility 3.96% 6.16%
Employees 557
Debt/Eq 0.10
Sales Y/Y TTM 12751.20%
Profit Margin -451.25%
Recom 1.40
Target Price 23.77
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q 40.47%
Payout -
Rel Volume 0.59
Prev Close 8.73
Sales Surprise 8.87%
EPS Surprise 6.32%
Sales Q/Q 12385.07%
Earnings Nov 07 AMC
Avg Volume 6.27M
Price 8.47
SMA20 -7.25%
SMA50 -13.32%
SMA200 -20.99%
Trades
Volume 3,717,428
Change -2.98%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-24-24 Initiated
UBS
Buy
$17
Jul-29-24 Downgrade
Piper Sandler
Overweight → Neutral
$19 → $10
Nov-20-23 Initiated
Goldman
Buy
$12
Sep-18-23 Reiterated
Barclays
Overweight
$40 → $18
May-30-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$11 → $17
Mar-27-23 Resumed
Wells Fargo
Equal Weight
$11
Jan-27-23 Upgrade
Piper Sandler
Neutral → Overweight
$11 → $14
Dec-09-22 Downgrade
Goldman
Buy → Neutral
$20 → $6
Oct-31-22 Initiated
Guggenheim
Neutral
Aug-18-22 Resumed
Wells Fargo
Equal Weight
$14
Jan-28-22 Upgrade
Stifel
Hold → Buy
$23 → $25
Dec-07-21 Resumed
Cowen
Outperform
Jun-10-21 Upgrade
JMP Securities
Mkt Perform → Mkt Outperform
$32
May-20-21 Downgrade
Piper Sandler
Overweight → Neutral
$35 → $18
May-19-21 Downgrade
Stifel
Buy → Hold
May-19-21 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
May-03-21 Initiated
Truist
Buy
$50
Apr-16-21 Initiated
Goldman
Buy
$97
Mar-08-21 Upgrade
H.C. Wainwright
Neutral → Buy
$50
Dec-15-20 Downgrade
H.C. Wainwright
Buy → Neutral
Show Previous Ratings
Nov-27-24 06:30AM
Nov-26-24 04:01PM
Nov-23-24 11:35AM
10:31AM
Nov-22-24 10:00AM
07:49AM
Loading…
07:49AM
Nov-14-24 08:00AM
Nov-08-24 08:03AM
Nov-07-24 05:45PM
04:42PM
(Associated Press Finance)
04:01PM
Oct-31-24 04:01PM
(GlobeNewswire) -5.43%
+7.18%
Oct-24-24 06:01PM
Oct-18-24 11:01AM
Oct-16-24 07:15PM
12:28PM
Loading…
Oct-12-24 12:28PM
Oct-10-24 10:39AM
Oct-09-24 08:03AM
Oct-04-24 08:30AM
Sep-26-24 08:15AM
Sep-16-24 06:29AM
Sep-14-24 05:32PM
Sep-06-24 09:30AM
Sep-03-24 05:00PM
Sep-02-24 06:15PM
Aug-27-24 04:36AM
Aug-16-24 05:00PM
Aug-14-24 07:15AM
Aug-09-24 12:23PM
09:27AM
05:30PM
Loading…
Aug-08-24 05:30PM
04:24PM
(Associated Press Finance)
04:01PM
Aug-01-24 10:01AM
Jul-31-24 05:31AM
Jul-29-24 06:24PM
04:01PM
08:31AM
Jul-19-24 05:00PM
Jul-17-24 02:29PM
Jul-14-24 05:45AM
Jul-11-24 02:23PM
Jul-08-24 06:46PM
12:30PM
Jun-28-24 07:00AM
04:05AM
Jun-21-24 05:00PM
06:36AM
Jun-20-24 10:02PM
08:47PM
Jun-10-24 10:15AM
May-29-24 06:20AM
04:58AM
May-28-24 08:14AM
08:06AM
May-24-24 04:01PM
11:18AM
May-23-24 05:00PM
May-22-24 06:40AM
May-17-24 05:15PM
May-16-24 09:30AM
May-13-24 02:25PM
12:42PM
May-11-24 10:00AM
May-10-24 02:03PM
01:35PM
12:55PM
12:33PM
11:25AM
10:58AM
May-09-24 08:57PM
04:27PM
(Associated Press Finance)
04:23PM
04:01PM
May-06-24 09:56AM
May-01-24 06:01AM
Apr-30-24 06:01AM
Apr-28-24 02:44PM
Apr-27-24 07:00AM
Apr-25-24 10:30AM
09:20AM
Apr-24-24 04:01PM
Apr-21-24 05:08AM
Apr-19-24 05:15PM
Apr-17-24 09:45AM
Apr-08-24 01:51PM
Apr-05-24 05:03AM
Mar-29-24 11:30AM
Mar-26-24 04:11AM
Mar-23-24 09:00AM
(The Wall Street Journal)
Mar-22-24 05:30PM
Mar-18-24 08:01PM
02:00AM
Mar-15-24 08:18AM
Mar-07-24 06:01AM
Mar-06-24 04:42AM
Mar-05-24 01:00PM
Mar-04-24 06:30AM
Mar-02-24 06:50AM
Mar-01-24 05:00PM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Vogt Frederick G Interim CEO & General Counsel Dec 02 '24 Option Exercise 0.00 10,417 0 214,662 Dec 04 04:31 PM BILINSKY IGOR Chief Operating Officer Dec 02 '24 Option Exercise 0.00 3,516 0 59,323 Dec 04 04:30 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Dec 02 '24 Option Exercise 0.00 3,906 0 64,633 Dec 04 04:30 PM Maynard Ryan D Director Nov 12 '24 Option Exercise 7.45 50,000 372,500 57,500 Nov 14 05:00 PM Maynard Ryan D Director Nov 12 '24 Sale 10.06 50,000 503,000 7,500 Nov 14 05:00 PM Maynard Ryan D Director Nov 12 '24 Proposed Sale 10.06 50,000 503,104 Nov 12 07:11 PM Vogt Frederick G Interim CEO & General Counsel Oct 14 '24 Option Exercise 0.00 20,834 0 213,096 Oct 16 06:33 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Oct 14 '24 Option Exercise 0.00 2,813 0 62,155 Oct 16 06:32 PM BILINSKY IGOR Chief Operating Officer Oct 14 '24 Option Exercise 0.00 2,813 0 57,235 Oct 16 06:30 PM Vogt Frederick G Interim CEO & General Counsel Sep 03 '24 Option Exercise 0.00 57,292 0 212,175 Sep 05 07:56 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Sep 03 '24 Option Exercise 0.00 27,345 0 71,233 Sep 05 07:54 PM BILINSKY IGOR Chief Operating Officer Sep 03 '24 Option Exercise 0.00 26,954 0 66,313 Sep 05 07:53 PM Bellemin Jean-Marc Chief Financial Officer Sep 03 '24 Option Exercise 0.00 23,438 0 41,239 Sep 05 07:52 PM Vogt Frederick G Interim CEO & General Counsel Jul 15 '24 Option Exercise 0.00 20,835 0 168,160 Jul 17 08:01 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jul 15 '24 Option Exercise 0.00 2,813 0 47,299 Jul 17 08:01 PM BILINSKY IGOR Chief Operating Officer Jul 15 '24 Option Exercise 0.00 2,813 0 42,571 Jul 17 08:00 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jun 03 '24 Option Exercise 0.00 3,906 0 46,468 Jun 05 08:07 PM BILINSKY IGOR Chief Operating Officer Jun 03 '24 Option Exercise 0.00 3,516 0 41,542 Jun 05 08:05 PM Vogt Frederick G Interim CEO & General Counsel Jun 03 '24 Option Exercise 0.00 10,417 0 151,751 Jun 05 08:04 PM Vogt Frederick G Interim CEO & General Counsel Apr 15 '24 Option Exercise 0.00 20,834 0 150,185 Apr 17 07:08 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Apr 15 '24 Option Exercise 0.00 2,812 0 43,989 Apr 17 07:07 PM BILINSKY IGOR Chief Operating Officer Apr 15 '24 Option Exercise 0.00 2,812 0 39,453 Apr 17 07:07 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 04 '24 Option Exercise 0.00 15,623 0 49,230 Mar 06 06:20 PM Vogt Frederick G Interim CEO & General Counsel Mar 04 '24 Option Exercise 0.00 41,662 0 140,800 Mar 06 06:19 PM MCPEAK MERRILL A Director Feb 20 '24 Buy 9.15 250,000 2,287,500 320,150 Feb 20 07:52 PM Dukes Iain D. Director Feb 20 '24 Buy 9.15 32,000 292,800 54,000 Feb 20 04:21 PM Rothbaum Wayne P. Director Feb 20 '24 Buy 9.15 5,000,000 45,750,000 28,067,333 Feb 20 04:11 PM Vogt Frederick G Interim CEO & General Counsel Jan 16 '24 Option Exercise 0.00 20,834 0 105,668 Jan 18 06:09 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jan 16 '24 Option Exercise 0.00 2,813 0 35,184 Jan 18 06:09 PM BILINSKY IGOR Chief Operating Officer Jan 16 '24 Option Exercise 0.00 2,813 0 31,444 Jan 18 06:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite